Short-term Outcomes of Hydrodistention with Intravesical Hyaluronic Acid (Cystistat®) Versus Hydrodistention Alone for Treating Interstitial Cystitis: A Randomized Controlled Trial

Background: Interstitial cystitis (IC) is a chronic, debilitating bladder disease that primarily affects middle-aged women and significantly their quality of life. Bladder hydrodistention the usual therapeutic diagnostic procedure, but symptoms tend to relapse. Adding hyaluronic acid has been shown improve outcomes. Objectives: To compare effects alone or with intravesical cystistat (40 mg sodium hyaluronate in 50 mL vial) treating IC/bladder pain syndrome (IC/BPS). Methods: This randomized controlled clinical trial was conducted Imam Reza Hospital Mashhad 2017. Twenty-four female IC/BPS patients were selected using examinations O`Leary-Sant IC questionnaire evaluate treatment effects. Patients history other diseases related urogenital system urination frequency less than eight times day excluded. The control group (n = 12) underwent under general anesthesia, intervention received addition weekly for four weeks, followed by monthly two months. Results: In group, mean baseline score 33.2 ± 1.9 reached 33.9 2.6 after three months, showing no significant change. 32.6 3.6 6.4 12.4 at end third month, which indicates better improvement (P < 0.001). this study, resolved 83.3% months treatment, while controls did not improve. Conclusions: Based on our instillation effective alone.